Russian Venture Company (RVC, a part of the Russian Direct Investment Fund, the Russian Federation's sovereign wealth fund) and Sber announced their intention to create a joint fund totaling $100 million to invest in technology and science-intensive startups.
ExoAtlet, an RVC Biofund portfolio company, has launched pilot projects for home exo-rehabilitation. The company's products — the ExoAtlet I and ExoAtlet Bambini exoskeletons — have attracted their first private customers, who have begun exercises right at home.
ExoAtlet, an RVC Biofund portfolio company, successfully completed trials and received a registration certificate for the ExoAtlet II exoskeleton, which was previously certified by the European Union. The training apparatus is the second exoskeleton in the company's lineup to achieve medical certification in the Russian market.
New Industry Ventures (a joint venture fund of Gazprom Neft, Gazprombank, RVC and VEB Ventures) supported the development of Russian video analytics system for occupational safety and industrial control using artificial intelligence and big data technologies.
The Russian direct investment Fund (RDIF, sovereign Fund of the Russian Federation) and the far East high technology Fund (DFWT, established with the participation of capital RVC) they invested RUB 300 million in the portfolio company of RDIF Motorika.
The new Industry Ventures venture Fund (a joint venture Fund of Gazprom Neft, Gazprombank, RVC and VEB Ventures) supported the project of creating an innovative visualization system and monitoring the progress of construction works.
The NTI venture Fund will invest RUB 180 million in the Tsels project (Medical screening systems LLC), one of the leaders of the Russian market for the analysis of medical images using artificial intelligence technologies.
The RBV Capital Fund, created with the participation of capital RVC and R-Pharm, invested 105 million rubles in PanDx, which is developing a multifunctional catheter “Izikat” for the treatment of severe diseases of the gastrointestinal tract.
ZeroAvia, a member of the Terra VC venture Fund portfolio created with the participation OF RVC capital, raised 37.7 million US dollars during round A. Earlier this year, the Fund invested in the company in a SAFE round. The amount of investments is not disclosed.
The results of the seventh annual study of the Russian venture investment market “Venture Barometer”, conducted by the research project Barometer on the initiative of venture investor and founder of A. Partners Alexey Solovyov, were published.
The volume of the venture transactions market in Russia in the first half of 2020 decreased by 9% to 240 million dollars, compared to 262.8 million dollars in the first half of 2019. At the same time, the number of transactions decreased by almost one and a half times — from 130 to 78 transactions. About 90% of the total investment during this period was in the expansion phase.
The first stage of testing the microwave radiothermometry (RTM) technology for diagnosing pulmonary complications in COVID-19 patients has been summed up. Their results showed that using this technology is a convenient and safe method of screening diagnostics in patients with COVID-19 with suspected pneumonia.
On November 10, Deputy General Director — the Investment Director of RVC, Alexey Basov, spoke at the Bank of Russia's next strategic session to discuss the Consultative Report “Development of Alternative Investment Mechanisms: Direct Investment and Crowdfunding”.
RVC and Chinese DeepBlue Technology Corporation signed the Memorandum of Understanding. The parties will develop cooperation in innovation and technology transfer to implement complex technology projects, including smart cities and Industry 4.0.